Skip to main content

Transurethral Bladder Neck Resection (TURBN)

Transurethral bladder neck resection (TURBN) is electrosurgical resection of the fibrotic scar tissue at the bladder neck — a first-line endoscopic alternative to transurethral incision for bladder neck contracture (BNC) and post-prostatectomy vesicourethral anastomotic stenosis (VUAS). The theoretical advantage is removal of scar rather than mere division, potentially reducing the substrate for re-fibrosis. In practice, TURBN and TUIBNC have comparable outcomes and the choice rests on surgeon preference and visualization.[1][2]

For the incision counterpart, see Transurethral Incision of BNC (TUIBNC). For the broader BNC framework and decision matrix, see Bladder Neck Contracture. For VUAS-specific reconstruction context, see VUAS.

AUA 2023 Practice Guideline​

The AUA Urethral Stricture Disease Guideline (2023) establishes that treatment of BNC after endoscopic prostate procedures can be performed with either bladder neck incision or bladder neck resection based on surgeon preference, with comparable outcomes expected. No studies directly compare the different treatment strategies for BNC after endoscopic prostate procedures. Repeat endoscopic treatment may be necessary. First-time VUAS treatment is successful in ~50–80% of cases with all techniques showing similar success. Patients should be counseled about post-procedure incontinence risk. For recalcitrant stenosis, robotic or open reconstruction is recommended (Conditional, Grade C), with robotic-assisted reconstruction patency rates 72.7–75%.[1]

Definition and Rationale​

TURBN uses a standard resectoscope with a loop electrode to excise fibrotic scar at the bladder neck, in contrast to TUIBNC which divides scar with a Collins / cold knife or laser. The conceptual goal is debulking the fibrotic substrate rather than relying on incision-driven splaying.[1][2]

FeatureTURBN (resection)TUIBNC (incision)
Energy / instrumentLoop electrode (standard resectoscope)Collins knife (cold or electrocautery) or laser
Tissue handlingRemoves scar tissueDivides scar without removal
Anatomic conceptDebulks fibrotic substrateSplays incised scar; perivesical fat at incision base
Best fitBulky / circumferential scarFocal / band-like contracture
Comparative outcomeNo difference (Rosenbaum 2021) — choice is surgeon preference[2]

Surgical Technique​

  1. Cystoscopic assessment. Visualize the contracture and evaluate extent (focal vs circumferential, dense vs band-like).
  2. Resection. Use a standard resectoscope with a loop electrode to resect fibrotic scar circumferentially or at targeted locations. Zhang 2021 describes resecting scar down to the circular muscle fibers at the bladder neck.[3]
  3. Depth control. Carry resection deep enough to remove fibrotic tissue but stop short of the external urinary sphincter distally and the ureteral orifices proximally — confirm orifice positions before resecting near the trigone.
  4. Optional adjunct injections. Some protocols add intralesional triamcinolone acetonide 40 mg/mL at multiple sites (commonly 8 injection points) at resection sites, with repeated postoperative cystoscopy-guided injections every 4 weeks × 3 — see TUIBNC for the comparative MMC vs corticosteroid framework.[3]

Outcomes​

SeriesnTechniquePopulationSuccessFollow-up
Rosenbaum 2021 (largest contemporary head-to-head)[2]49 resection vs 11 incisionTURBN vs BNIPost-BPH surgery53% overall; type of treatment did NOT influence outcome (p = NS)Variable
Zhang 2021[3]28TURBN + intra-op + postop triamcinoloneHighly recurrent BNC, multiple prior failures92.9%2.8 yr
Woodhouse 1979[4]—TURBN vs BNIPost-TURPEqually effective—

The Rosenbaum 2021 series is the largest contemporary cohort directly comparing resection and incision within the same institution. Of 60 patients, 82% underwent resection and 18% underwent incision; the type of BNC treatment did not significantly influence outcome (p = NS) — confirming AUA's equivalence position.[2]

Practice Patterns​

A survey of 84 urologic departments in Germany (Pfalzgraf 2017) found transurethral resection was the most commonly used treatment modality for BNC after radical prostatectomy, followed by cold knife incision, hot knife incision, and dilation. However, among the 56 institutions that followed a therapeutic algorithm, 33 different approaches were identified — highlighting the heterogeneity in practice and the absence of standardized protocols.[5]

Risk Factors for Failure​

Identical to those for TUIBNC:

  • Shorter interval between initial prostate surgery and BNC onset — earlier-onset BNC (median 6.5–7.5 mo) had significantly higher recurrence than later onset (median 10–12 mo; p = 0.01–0.046).[2]
  • Prior TURP vs HoLEP — BNC treatment success was significantly higher after HoLEP than after TURP (100% vs 48%; p = 0.026), though small cohort.[2]
  • ≥ 2 prior endoscopic BNC procedures — most consistent failure predictor across resection and incision series.[6][7]
  • >10 pack-year smoking — p = 0.039.[7]
  • Pelvic radiation — lower success.[1]

Complications​

ComplicationRate / note
Stress urinary incontinencePrincipal concern — up to 78% of post-prostatectomy BNC patients have concomitant SUI; counsel about de novo / worsened incontinence[7]
Recurrence~47% in Rosenbaum cohort required additional treatment; usually within first months[2]
Bleeding, UTI, perforationUncommon; standard endoscopic risks
Urethral wall stent salvageFor severe recurrent BNC after aggressive transurethral resection — 52% stabilization after a single stent; 76% after multiple stents (Magera 2009)[8]

Resection vs Incision — Bottom Line​

The available evidence consistently demonstrates that bladder neck resection and incision are equally effective — no comparative study has shown superiority of one over the other.[1][2][4] Choice is appropriately left to surgeon preference and intraoperative anatomy:

  • Resection may be favored when there is a large volume of scar to debulk.
  • Incision may be preferred for technical simplicity and speed.

Both can be combined with adjunctive corticosteroids or Mitomycin-C in recurrent cases — see TUIBNC for the full adjunct comparison.

When to Escalate​

For patients who fail repeated endoscopic treatment (resection or incision):

  • Urethral wall stent + AUS — 76% cumulative patency with multiple stents (Magera 2009).[8]
  • Robotic / open reconstruction — Y-V plasty or reanastomosis; 72.7–75% patency, with significant subsequent SUI risk requiring AUS.[1][9] See Y-V Plasty and Combined Abdominoperineal Approach.
  • Permanent urinary diversion — reserved for the most refractory cases (~5–8% of refractory BNC).[10]

Key Principles​

  • TURBN and TUIBNC are equivalent first-line endoscopic treatments per AUA 2023 — choice rests on surgeon preference.[1][2]
  • Stop short of the external sphincter distally and ureteral orifices proximally — the principal anatomic safety boundaries.
  • Up to 78% of post-prostatectomy BNC patients have concomitant SUI — counsel before any procedure; AUS placement at ~3 months post-treatment is feasible with > 90% urethral patency preserved.[7]
  • TURBN + repeat triamcinolone (Zhang 2021 protocol) achieved 92.9% success in highly recurrent BNC at 2.8-yr follow-up — useful when standardized adjunct protocol is selected.[3]
  • Most consistent failure predictor: ≥ 2 prior endoscopic procedures (resection or incision).[6][7]
  • Practice is heterogeneous — 33 different algorithms across 56 institutions in Pfalzgraf 2017; no single protocol dominates.[5]
  • Escalate to robotic / open reconstruction after 2 endoscopic failures — match to radiation history and existing incontinence.[1][9]

References​

1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. Urethral stricture disease guideline amendment (2023). J Urol. 2023;210(1):64-71. doi:10.1097/JU.0000000000003482.

2. Rosenbaum CM, Vetterlein MW, Fisch M, et al. Contemporary outcomes after transurethral procedures for bladder neck contracture following endoscopic treatment of benign prostatic hyperplasia. J Clin Med. 2021;10(13):2884. doi:10.3390/jcm10132884.

3. Zhang L, Liu S, Wu K, Mu X, Yang L. Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections. World J Urol. 2021;39(2):527-532. doi:10.1007/s00345-020-03224-w.

4. Woodhouse E, Barnes R, Hadley H, Rothman C. Fibrous contracture of bladder neck: cause, prevention, and treatment. Urology. 1979;13(4):393-4. doi:10.1016/0090-4295(79)90337-6.

5. Pfalzgraf D, Siegel FP, Kriegmair MC, Wagener N. Bladder neck contracture after radical prostatectomy: what is the reality of care? J Endourol. 2017;31(1):50-56. doi:10.1089/end.2016.0509.

6. Nealon SW, Bhanvadia RR, Badkhshan S, et al. Transurethral incisions for bladder neck contracture: comparable results without intralesional injections. J Clin Med. 2022;11(15):4355. doi:10.3390/jcm11154355.

7. Ramirez D, Zhao LC, Bagrodia A, et al. Deep lateral transurethral incisions for recurrent bladder neck contracture: promising 5-year experience using a standardized approach. Urology. 2013;82(6):1430-5. doi:10.1016/j.urology.2013.08.018.

8. Magera JS, Inman BA, Elliott DS. Outcome analysis of urethral wall stent insertion with artificial urinary sphincter placement for severe recurrent bladder neck contracture following radical prostatectomy. J Urol. 2009;181(3):1236-41. doi:10.1016/j.juro.2008.11.011.

9. Zang Z, Shao D, Zhang H, et al. Extraperitoneal laparoscopic modified Y-V plasty for the treatment of refractory bladder neck contracture. J Vis Exp. 2022;(184). doi:10.3791/64011.

10. Brede C, Angermeier K, Wood H. Continence outcomes after treatment of recalcitrant postprostatectomy bladder neck contracture and review of the literature. Urology. 2014;83(3):648-52. doi:10.1016/j.urology.2013.10.042.